Lucerastat
Phase 3Small molecule
Idorsia Pharmaceuticals Ltd.Lucerastat is one of 8 small molecule programs targeting Fabry Disease. It is currently in Phase 3.
1
Indications
9
Total Trials
2
Active Trials
7
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Fabry Disease
#DrugCompanyPhaseTrials
1Venglustat
SanofiPhase 3
ELFABRIO
Chiesi Farmaceutici S.p.A.Phase 3
Replagal
TakedaPhase 3
Migalastat Hcl
AAmicus Therapeutics
Phase 3
Lucerastat
Idorsia Pharmaceuticals Ltd.Phase 3
PRX-102 /kg
Chiesi Farmaceutici S.p.A.Phase 3
Zemplar
AbbViePreclinical
Biological Data
UUniversity Hospital, Bordeaux
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Fabry Disease5 trials
Show 2 more trials
Tics3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lucerastat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company